Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in pediatric relapsing NMOSD
NCT04155424Phase 3Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of eculizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Alexion Pharmaceuticals. Primary endpoints: Annualized Relapse Rate at 53 weeks and Time to First On-trial Relapse at 53 weeks. Started Jan 2020; status: terminated.
02
Drugs
eculizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT04155424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04155424.